Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Carcinoma, Basal Cell 7Carcinoma, Non-Small-Cell Lung 5Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 3Keratosis, Actinic 3Cholangiocarcinoma 3Tongue Neoplasms 2Pleural Diseases 2Non-Muscle Invasive Bladder Neoplasms 2Mycosis Fungoides 2Mesothelioma, Malignant 2Carcinoma, Transitional Cell 2Bile Duct Neoplasms 2Basal Cell Nevus Syndrome 2Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Stomatitis 1Skin Neoplasms 1Sezary Syndrome 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Photosensitivity Disorders 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pain 1Neoplasms 1Lymphoma, T-Cell, Cutaneous 1Lymphoid Interstitial Pneumonia 1Lung Neoplasms 1

Interventions

Photochemotherapy 1Drug Therapy 1Dihematoporphyrin Ether 11-phenyl-3,3-dimethyltriazene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Epitheliod Malignant Pleural Mesothelioma × 1-phenyl-3,3-dimethyltriazene × Clear all
NCT02153229 2025-12-26

MPM-PDT

Abramson Cancer Center at Penn Medicine

Phase 2 Active not recruiting
52 enrolled
Other solid neoplasmThoracic

Epitheliod Malignant Pleural Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡